Also trades as: ACONW (NASDAQ) · $vol 0M
ACON NASDAQ
Aclarion, Inc.
1W: -8.1%
1M: +3.0%
3M: -22.5%
YTD: -52.2%
1Y: -68.6%
3Y: -100.0%
$2.38
-0.06 (-2.46%)
Weekly Expected Move ±10.9%
$2
$2
$2
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (32)
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site
Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates
Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Aclarion (ACON) Upgraded to Buy: Here's Why
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates
Sonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Teladoc (TDOC) Reports Q1 Loss, Beats Revenue Estimates
Aclarion announces $2.5M stock repurchase plan
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet
Aclarion (NASDAQ:ACON) & InnovAge (NASDAQ:INNV) Head-To-Head Comparison
Aclarion Publishes 2026 Shareholder Letter from the Chairman
Aclarion Publishes 2026 Shareholder Letter from the Chairman
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Aclarion Provides 2025 Update and 2026 Corporate Outlook
Aclarion Provides 2025 Update and 2026 Corporate Outlook
Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.